Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.

We report here the design, synthesis, and pharmacological properties of a series of compounds related to tranylcypromine (9), which itself was discovered as a lead compound in a high-throughput screening campaign. Starting from 9, which shows modest activity as a 5-HT(2C) agonist, a series of 1-aminomethyl-2-phenylcyclopropanes was investigated as 5-HT(2C) agonists through iterative structural modifications. Key pharmacophore feature of this new class of ligands is a 2-aminomethyl-trans-cyclopropyl side chain attached to a substituted benzene ring. Among the tested compounds, several were potent and efficacious 5-HT(2C) receptor agonists with selectivity over both 5-HT(2A) and 5-HT(2B) receptors in functional assays. The most promising compound is 37, with 120- and 14-fold selectivity over 5-HT(2A) and 5-HT(2B), respectively (EC(50) = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes, respectively). In animal studies, compound 37 (10-60 mg/kg) decreased immobility time in the mouse forced swim test.

[1]  A. Burger,et al.  Arylcycloalkylamines. I. 2-Phenylcyclopropylamine , 1948 .

[2]  K. H. Shaughnessy,et al.  Aqueous-phase, palladium-catalyzed cross-coupling of aryl bromides under mild conditions, using water-soluble, sterically demanding alkylphosphines. , 2004, The Journal of organic chemistry.

[3]  I. Lucki,et al.  Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[5]  M. Isaac.  Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. , 2005, Current topics in medicinal chemistry.

[6]  Bryan L Roth,et al.  N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity , 2008, Neuropsychopharmacology.

[7]  K. Marquis,et al.  Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. , 2006, CNS drug reviews.

[8]  I. Lucki,et al.  Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents , 2007, Psychopharmacology.

[9]  E. Janovitz,et al.  Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor. , 2007, Journal of medicinal chemistry.

[10]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[11]  P. Delgado,et al.  Hallucinogens, serotonin and obsessive-compulsive disorder. , 1998, Journal of psychoactive drugs.

[12]  D. Hoffman,et al.  trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D(2)/D(4) receptor antagonists as potential antipsychotic agents. , 2000, Journal of medicinal chemistry.

[13]  Brian M. Smith,et al.  Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. , 2008, Journal of medicinal chemistry.

[14]  Bryan L Roth,et al.  G-protein-coupled receptors at a glance , 2003, Journal of Cell Science.

[15]  S. Krishnamurthy,et al.  A HIGHLY EFFICIENT AND GENERAL N-MONOMETHYLATION OF FUNCTIONALIZED PRIMARY AMINES VIA FORMYLATION AND BORANE-METHYL SULFIDE REDUCTION , 1982 .

[16]  B. Harrison,et al.  Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. , 2004, Bioorganic & Medicinal Chemistry Letters.

[17]  M. Dallman,et al.  Compulsive behavior in the 5-HT2C receptor knockout mouse , 2003, Physiology & Behavior.

[18]  B. Roth,et al.  The expanded biology of serotonin. , 2009, Annual review of medicine.

[19]  P. Seymour,et al.  CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity , 2007, Neuropharmacology.

[20]  B. Roth,et al.  Molecular biology of serotonin receptors structure and function at the molecular level. , 2002, Current topics in medicinal chemistry.

[21]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[22]  L. Tecott,et al.  Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. , 2004, European journal of pharmacology.

[23]  B. Roth,et al.  Insights into the structure and function of 5-HT2 familyserotonin receptors reveal novel strategies for therapeutic target development , 2001, Expert opinion on therapeutic targets.

[24]  Norio Miyaura,et al.  Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds , 1995 .

[25]  M. Millan,et al.  5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. , 1997, European journal of pharmacology.

[26]  L. Parsons,et al.  Enhanced Locomotor, Reinforcing, and Neurochemical Effects of Cocaine in Serotonin 5-Hydroxytryptamine 2C Receptor Mutant Mice , 2002, The Journal of Neuroscience.

[27]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[28]  David Julius,et al.  Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.

[29]  M. J. Sloan,et al.  Fluorinated phenylcyclopropylamines. 1. Synthesis and effect of fluorine substitution at the cyclopropane ring on inhibition of microbial tyramine oxidase. , 2004, Journal of medicinal chemistry.

[30]  A. Sleight,et al.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[31]  D. Baker,et al.  Modeling structurally variable regions in homologous proteins with rosetta , 2004, Proteins.

[32]  D. J. Price,et al.  Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.

[33]  S. Salvadori,et al.  Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism. , 2003, Bioorganic & medicinal chemistry.

[34]  B. Roth,et al.  The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .

[35]  B. Roth.  Multiple serotonin receptors: clinical and experimental aspects. , 1994, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[36]  W. Kroeze,et al.  The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis , 1998, Biological Psychiatry.

[37]  C. Overberger,et al.  Synthesis and Optical Properties of Asymmetric Polyamides Derived from Optically Active Cyclic Dicarboxylic Acids , 1971 .